CAY10595 manufacturers
- CAY10595
-
- $46.00
-
2026-04-20
- CAS:916047-16-0
- Purity: 99.95%
- Supply Ability: 10g
- CAY10595
-
- $46.00
-
2026-04-20
- CAS:916047-16-0
- Purity: 99.95%
- Supply Ability: 10g
|
| | CAY10595 Basic information |
| Product Name: | CAY10595 | | Synonyms: | CAY10595;CAY10595 Exclusive;IXKFWNVFUXXEFY-UHFFFAOYSA-N;Spiro[3H-indole-3,3'-pyrrolidine]-1(2H)-acetic acid, 5-chloro-1'-[(5-chloro-2-fluorophenyl)methyl]-2,2',5'-trioxo-;CAY10595,CAY-10595 | | CAS: | 916047-16-0 | | MF: | C20H13Cl2FN2O5 | | MW: | 451.23 | | EINECS: | | | Product Categories: | | | Mol File: | 916047-16-0.mol |  |
| | CAY10595 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:10): 0.5 mg/ml; Ethanol: 25 mg/ml | | form | A crystalline solid |
| | CAY10595 Usage And Synthesis |
| Description | The biological effects of prostaglandin D2 (PGD2) are transduced by at least two 7-transmembrane G protein-coupled receptors, designated DP1 and CRTH2/DP2. In humans, CRTH2/DP2 is expressed on Th2 cells, eosinophils, and basophils where it mediates the chemotactic activity of PGD2.1 CAY10595, as a racemic mixture, is a potent CRTH2/DP2 receptor antagonist that binds to the human receptor with a Ki value of 10 nM.2 The R enantiomer of CAY10595 is significantly more potent exhibiting Ki values of 5.3 and 5 nM at the human and murine CRTH2/DP2 receptor, respectively. The R enantiomer of CAY10595 inhibits eosinophil chemotaxis induced by 13,14-dihydro-15-keto-PGD2 with an IC50 value of 7.3 nM.2 | | Uses | CAY10595 is a potent CRTH2/DP2 receptor antagonist that binds to the human receptor with a Ki of 10 nM. | | in vivo | Administration of the DP2 antagonist CAY10595 slightly delays the development of CIA. Treatment with CAY10595 reduces IgG2a anti-CII levels without modification of IgG anti-CII levels[2]. | | IC 50 | DP: 10 nM (Ki) | | References | 1. Hirai, H., Tanaka, K., Yoshie, O., et al. Prostaglandin D2 selectivity induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2 J. Exp. Med. 193(2),255-261(2001).
2. Crosignani, S., Page, P., Missotten, M., et al. Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases J. Med. Chem. 51,2227-2243(2008). |
| | CAY10595 Preparation Products And Raw materials |
|